GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Net-Net Working Capital

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Net-Net Working Capital : $0.14 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Lexicon Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $0.14.

The industry rank for Lexicon Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

LXRX's Price-to-Net-Net-Working-Capital is ranked worse than
79.5% of 927 companies
in the Biotechnology industry
Industry Median: 4 vs LXRX: 11.29

Lexicon Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for Lexicon Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Net-Net Working Capital Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.74 0.43 0.32 0.14

Lexicon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.17 0.52 0.33 0.14

Competitive Comparison of Lexicon Pharmaceuticals's Net-Net Working Capital

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.



Lexicon Pharmaceuticals Net-Net Working Capital Calculation

Lexicon Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(170.026+0.75 * 1.01+0.5 * 0.381-136.319
-0-0)/244.925
=0.14

Lexicon Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(170.026+0.75 * 1.01+0.5 * 0.381-136.319
-0-0)/244.925
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Lexicon Pharmaceuticals  (NAS:LXRX) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Lexicon Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Executives
Philippe Amouyal director C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats director, officer: President and CEO 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner officer: SVP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade officer: EVP, Gen. Counsel 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott officer: VP, Human Resources 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a. director, 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc director, 10 percent owner 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth officer: VP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub officer: SVP, Regulatory & QA 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander officer: VP, Finance and Accounting 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz officer: SVP, Chief Medical Officer 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer officer: VP, Finance & Acctg 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Headlines